Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964388 · ClinicalTrials.gov registry record · Phase 2
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
A Phase 2 study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04964388: Clinical Trial Phase 2 study, sponsored by University of Mississippi Medical Center.
NCT04964388 is a Phase 2 study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04964388, a Phase 2 study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)
Primary Outcome
The change in TBS from baseline to six months and one year after the initiation of a GLP-1 receptor agonist. TBS will be assessed by DXA scans done at baseline, six months and one year.
Interventions
- DRUG GLP-1 receptor agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-11-09 |
| Est. Completion | 2023-07-01 |
| Phase | Phase 2 |
Why NCT04964388 stopped before completion
NCT04964388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which GLP-1 receptor agonist is the first listed.
NCT04964388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04964388 about?
NCT04964388 is a clinical study titled "Effect of GLP-1 Receptor Agonists on Trabecular Bone Score". This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)
What is the current status of trial NCT04964388?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2021-11-09. Estimated completion is 2023-07-01.
What interventions are being tested in trial NCT04964388?
The interventions under investigation include: GLP-1 receptor agonist (DRUG).
Who is sponsoring clinical trial NCT04964388?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04964388's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI